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Figure 2
Crude incidence rates of CKD and cumulative exposure to potentially nephrotoxic 
antiretrovirals
Figure 3
Unadjusted and adjusted incidence rates of CKD per year of additional exposure to 
potentially nephrotoxic antiretrovirals
Figure 1A
Use of potentially nephrotoxic antiretrovirals at baseline : Exposure to ARVs at/before 
baseline
Figure 1B
Use of potentially nephrotoxic antiretrovirals at baseline : Median exposure to ARVs 
among those ever started
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Among those started, % on ARV at baseline
87.0                   56.2                  78.5                    64.3                     32.6            10.2                   61.4
IQR; interquartile range.  Baseline: first eGFR measured during prospective follow-up in D:A:D after 1/1/2004.  
TDF; tenofovir.  ATV; atazanavir.  ATV/r; ritonavir boosted atzazanavir.  LPV/r; ritonavir-boosted lopinavir.  Other PI/r; other ritonavir-boosted 
protease inhibitor.  IDV; indinavir.  ABC; abacavir
Figure 1A
Use of potentially nephrotoxic antiretrovirals at baseline
Exposure to ARVs at/before baseline
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Among those stopped, median years (IQR) since last stopping
0.7 (0.3–1.5)     1.2 (0.4–2.5)    0.9 (0.3–1.8)    1.2 (0.5–2.3)    3.4 (1.8–5.1)    4.7 (3.0–6.4)    2.0 (0.8–3.7)  
IQR; interquartile range.  Baseline: first eGFR measured during prospective follow-up in D:A:D after 1/1/2004.  
TDF; tenofovir.  ATV; atazanavir.  ATV/r; ritonavir boosted atzazanavir.  LPV/r; ritonavir-boosted lopinavir.  Other PI/r; other ritonavir-boosted 
protease inhibitor.  IDV; indinavir.  ABC; abacavir
Figure 1B
Use of potentially nephrotoxic antiretrovirals at baseline
Median exposure to ARVs among those started
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0 – 1 years 1 – 2 yearsX
Tenofovir Atazanavir/r              Lopinavir/r              Other PI/r               Abacavir
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0 (never exposed)Cumulative 
exposure 
to drug
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_
5 – 6 years > 6 years
CKD; chronic kidney disease; confirmed (>3 months part) eGFR < 60 mL/min/1.73m2
CKD; chronic kidney disease; confirmed (>3 months part) eGFR < 60 mL/min/1.73m2
Multivariate models were adjusted for gender race, HIV exposure group, D:A:D enrolment cohort, D:A:D participating cohort,  prior CVD, 
age, CD4 nadir, GFR at baseline, baseline date and hepatitis B/C, AIDS diagnosis within the past 12 months, smoking status, BMI, family 
history of CVD, CD4, viral load, anaemia, diabetes, hypertension and cART (on/off) as time updated variables. A separate category was 
included for missing data where data was missing.  Models were additionally adjusted for cumulative exposure to indinavir.
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